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Abstract 
Background: Asymptomatic Leishmania infections outnumber clinical infections on the Indian subcontinent (ISC), 
where disease reservoirs are anthroponotic. Diagnostics which detect active asymptomatic infection, which are suit-
able for monitoring and surveillance, may be of benefit to the visceral leishmaniasis (VL) elimination campaign on the 
ISC.
Methods: Quantitative polymerase chain reaction (qPCR), loop-mediated isothermal amplification (LAMP), and the 
direct agglutination test (DAT) were carried out on blood samples, and the Leishmania antigen ELISA was carried 
out on urine samples collected from 720 household and neighbouring contacts of 276 VL and post–kala-azar der-
mal leishmaniasis (PKDL) index cases, with no symptoms or history of VL or PKDL, in endemic regions of Bangladesh 
between September 2016 and March 2018.
Results: Of the 720 contacts of index cases, asymptomatic infection was detected in 69 (9.6%) participants by a com-
bination of qPCR (1.0%), LAMP (2.1%), DAT (3.9%), and Leishmania antigen ELISA (3.3%). Only one (0.1%) participant 
was detected positive by all four diagnostic tests. Poor agreement between tests was calculated using Cohen’s kappa 
(κ) statistics; however, the Leishmania antigen ELISA and DAT in combination captured all participants as positive by 
more than one test. We find evidence for a moderately strong association between the index case being a PKDL case 
(OR 1.94, p = 0.009), specifically macular PKDL (OR 2.12, p = 0.004), and being positive for at least one of the four tests.
Conclusions: Leishmania antigen ELISA on urine detects active asymptomatic infection, requires a non-invasive 
sample, and therefore may be of benefit for monitoring transmission and surveillance in an elimination setting in 
combination with serology. Development of an antigen detection test in a rapid diagnostic test (RDT) format would 
be of benefit to the elimination campaign.
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Background
Infection with the parasite Leishmania donovani (L. 
donovani) usually manifests as asymptomatic infection 
with a small risk of progression to visceral leishmania-
sis (VL), which in the absence of treatment is consid-
ered fatal [1]. Progression from asymptomatic infection 
to symptomatic disease was estimated to be between 
5.6 and 15.2% in individuals with high anti-Leishmania 
antibody titres, as measured by the direct agglutination 
test (DAT), in India and Nepal [2]. Globally, the ratio of 
asymptomatic to symptomatic VL varies [3]. In Bangla-
desh, the number of asymptomatic cases was found to 
outnumber symptomatic cases by 4 to 1 [4].
Asymptomatic infection is of importance to VL 
endemic regions of the Indian subcontinent (ISC—India, 
Nepal, and Bangladesh), where the disease has been 
the target of an elimination campaign since 2005 [5, 6]. 
The epidemiology of VL is cyclical, and outbreaks occur 
approximately every 15  years on the ISC [7]. Asymp-
tomatic carriers may represent a potential source of 
transmission in a region where parasite reservoirs are 
anthroponotic [8]. However, it is yet to be determined 
whether asymptomatically infected humans are infec-
tive to sand flies. A study in a small number of asympto-
matically infected dogs showed that L. infantum parasites 
were transmittable to sand flies [9]; however, no human 
data with L. donovani have yet been recorded. Sixteen 
(8.2%) asymptomatic individuals who converted to VL 
within 2  years in a study in Bangladesh were found to 
have significantly higher anti-rK39 antibody titres than 
their counterparts who did not progress [10].
The rK39 enzyme-linked immunosorbent assay 
(ELISA), rK39 rapid diagnostic test (RDT), and the DAT 
measure the presence of anti-Leishmania antibodies 
[11–14]. These antibodies have been found to persist for 
months or years after infection, with patients in the VL 
endemic region of Muzaffarpur, India found positive by 
rK39 RDT (39.0%) and DAT (53.0%)  ≥ 15  years post-
treatment [15]. Therefore, a clinical history is required 
to determine whether a positive result is due to active 
or previous infection, or a previous asymptomatic infec-
tion that will not progress to disease. Tests which detect 
active infection, such as quantitative real-time polymer-
ase chain reaction (qPCR), loop-mediated isothermal 
amplification (LAMP), or Leishmania antigen ELISA, 
could be used as tools to monitor active asymptomatic 
infection and quickly identify areas with increasing active 
transmission.
Highly sensitive qPCR was shown to be an effective 
technique for diagnosis of VL and monitoring of treat-
ment response, and could be of value in an elimination 
setting [16]. LAMP enables the robust, fast, simple, 
and highly specific amplification of nucleic acids and 
does not require a thermocycler or cold chain; the Loo-
pamp™ Leishmania Detection Kit (Eiken Chemical Co., 
Japan) targets both the 18S rDNA and kinetoplast DNA 
(kDNA), and was previously demonstrated to have sen-
sitivity of 92% in patients with suspected VL in Ethio-
pia [17]. Similarly high sensitivity of 98% and 100% was 
seen in a study in Sudan with the Loopamp™ Leishmania 
Detection Kit when DNA was extracted from peripheral 
blood using boil-and-spin and QIAamp DNA mini kits 
(Qiagen, Hilden, Germany), respectively [18]. Finally, 
the Leishmania antigen ELISA (Clin-Tech, Guilford, 
UK) detects low-molecular-weight Leishmania carbohy-
drates excreted in the urine and therefore detects active 
infection and uses a non-invasive sample type. A study 
found sensitivity to range from 77% (n = 13) in Bangla-
desh to 87% (n = 46) in Ethiopia, although more data are 
needed to evaluate this assay [19]. The clinical utility of 
the Leishmania antigen ELISA is yet to be determined in 
an asymptomatic population.
To determine the utility of the DAT, kDNA qPCR, 
Eiken LAMP, and the Leishmania antigen ELISA for 
monitoring and surveillance of asymptomatic Leishma-
nia infection in an elimination setting, we tested samples 
collected from household or neighbouring contacts of 
index cases from endemic regions of Bangladesh. In this 
study, asymptomatic infection is defined as being posi-
tive for at least one of the aforementioned tests. Risk fac-
tors for asymptomatic infection were also investigated. 
We then compare the measure of prevalence with that 
obtained from a latent class analysis, in which the test 
characteristics of our four tests are formally synthesised 
through the use of a probability model.
Methods
Asymptomatic visceral leishmaniasis clinical samples
Blood and urine samples from 720 clinically healthy 
household and neighbouring contacts in adjacent house-
holds of 276 VL or PKDL index cases (between 1 and 
8 contacts per index case), aged 5 to 60  years, with no 
symptoms or history of VL or PKDL, were collected 
between September 2016 and March 2018. Symptoms 
considered as exclusion criteria included fever, presence 
of a rash, enlargement of the spleen or liver, and weak-
ness, among others. The study was conducted in the 
VL endemic districts of Mymensingh, Gazipur, Tangail, 
Narail, Jamalpur, Pabna, and Brahmanbaria in Bangla-
desh. Symptoms considered included presence of fever, 
rash, loss of appetite, weight loss, lymph node enlarge-
ment, and abdominal enlargement and pain. Demo-
graphic and clinical parameters were recorded. Blood 
and urine samples were transported to Dhaka using a 
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cold chain for processing and laboratory analysis using 
DAT and LAMP. Urine and DNA samples for Leishmania 
antigen ELISA and qPCR, respectively, were transported 
on ice to the UK from Bangladesh and stored at −20 °C 
until testing.
DNA extraction
DNA was extracted in three different ways: (1) DNA was 
extracted from 100 µl whole blood and eluted in 200 µl 
buffer using DNeasy blood and tissue DNA extraction 
kits (Qiagen, Hilden, Germany) as per the manufactur-
er’s instructions. (2) Boil-and-spin extractions were car-
ried out by pretreating whole blood samples with sodium 
dodecyl sulphate (SDS). Briefly, 10% SDS solution was 
mixed with blood to a final concentration of 5% and 
stored at −20 °C. Once defrosted, samples were inverted 
10 times and allowed to stand at room temperature for 
10  min. Samples were further inverted, and 400  µl of 
distilled water was added before incubation at 90  °C 
for 10  min. Tubes were then centrifuged at maximum 
speed for 3 min, and the supernatants stored for testing. 
(3) DNA was extracted from dried blood spots (DBS). 
Whole blood was air-dried onto Whatman filter paper 
(GE Healthcare Life Sciences, Buckinghamshire, UK) 
for 30 min at room temperature and stored in individual 
bags. Discs of 7 mm were punched out of the paper and 
added to an Eppendorf tube with 50 µl of double-distilled 
water. Tubes were incubated at 90 °C for 10 min followed 
by centrifugation for 3 min at maximum speed. Superna-
tants were stored at −20 °C for testing.
qPCR
Real-time PCR (qPCR) was performed on DNA extracted 
from whole blood using Qiagen DNeasy kits (Qiagen, 
Germany) [17]. An aliquot of 1.25  μl DNA was added 
to 11.25 μl of an amplification mixture containing 2.5 μl 
QuantiFast master mix (Qiagen, Germany), 0.4  μM 
kDNA forward primer, 0.4  μM kDNA reverse primer, 
and 0.2  μM kDNA FAM probe. Amplification was per-
formed on a Qiagen Rotor-Gene Q system with the fol-
lowing reaction conditions: 5  min at 95  °C, followed by 
40 cycles of 15  s at 95  °C and 30  s at 60  °C. Data were 
analysed using the Rotor-Gene Q series software (Qia-
gen, Germany). Standard curve analysis was performed 
using Leishmania donovani DNA (positive control), and 
the data were used to set a qPCR threshold. Samples 
with cycle threshold (Ct) < 34 were considered positive to 
reduce detection of non-specific amplification.
Loop‑mediated isothermal amplification (LAMP)
LAMP was run on DNA extracted from whole blood 
using the DNeasy blood and tissue DNA extraction 
kits (Qiagen, Germany), boil-and-spin extraction, and 
extraction from dried blood spots as described above. 
Loopamp™ Leishmania detection kits (Eiken Chemical 
Co., Ltd., Tokyo, Japan) were used. Samples to be tested 
were made up to total volume of 30  µl by adding 3  µl 
DNA sample to 27 µl of water. The lids of the tubes were 
then closed, and the sample were mixed with the mas-
ter mix contained in the tube cap by inverting the tubes 
and leaving them to stand for 2 min cap-side down. The 
tubes were inverted five times, spun down, and incu-
bated at 65 °C for 40 min, then 80 °C for 5 min. Results 
were visualised under blue LED light illumination, using 
the fluorescence visual check unit of   the HumaLoop 
M incubator (HUMAN, Wiesbaden, Germany). Results 
were read by two technicians blinded to each other. A 
third technician was consulted in the event of disagree-
ment, and the majority decision used.
Direct agglutination test (DAT)
The DAT was carried out in Bangladesh and performed 
as previously described [20]. Following a dilution of sera 
1:100, the samples were further diluted in eight twofold 
serial dilutions. Where samples did not react in the first 
dilution, the end titre was read as < 1:200. Where samples 
still reacted at the final dilution, the end titre was read as 
> 1:25,600. The threshold for a positive DAT result was 
set at ≥ 1:1600 as previously used by Hasker et  al. for 
detection of asymptomatic infection [20].
Leishmania antigen ELISA
The Leishmania antigen ELISA (Clin-Tech, Guild-
ford, UK) was performed on urine samples as per 
the manufacturer’s instruction. Briefly, samples were 
diluted 1:20 with assay diluent. One hundred micro-
litres of antigen calibrators and diluted samples was 
added to a pre-coated 96-well plate and incubated 
at 37  °C for 30  min. Following four washes, 100  µl of 
working strength tracer was added to the wells and 
incubated at 37 °C for 30 min. Following a further four 
washes, 100  µl of TMB substrate was added to each 
well and incubated uncovered between 18° and 25  °C 
for 30  min. One hundred microlitres of stop solution 
was then added to each well. A standard curve was 
included on each plate. The optical densities (OD) 
were read at 450  nm and blanked on air or with the 
620 nm reading within 30 min of addition of stop solu-
tion. Four-parameter curve-fitting software was used 
to calculate the concentration (UAU/ml) of each sam-
ple. IBM SPSS Statistics version 24 software was used 
to generate receiver-operating characteristic (ROC) 
curves using 720 asymptomatic cases and 80 VL cases 
to determine the threshold in UAU/ml that gave a sen-
sitivity of 98.8% and a specificity of 96.7%. The area 
under the curve (AUC) was calculated.
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Statistical analysis
Data were analysed in R Studio version 1.1.456. Discrete 
variables were summarised as counts and percentages. 
Continuous variables were summarised as the median 
and interquartile range (IQR). The software package 
‘Venny’ was used to create Venn diagrams for compari-
son of diagnostic tests [21].
Percentage agreement between diagnostic tests and 
Cohen’s kappa (κ) statistics with p values to measure 
agreement between diagnostic tests were calculated with 
the irr package version 0.84.1 in R. Logistic regression 
was used to regress the asymptomatic L. donovani infec-
tion (defined as positive for at least one of the four tests) 
outcome variable onto potential risk factor variables 
identified in the literature. Latent class analysis was used 
to estimate diagnostic accuracy and prevalence [22]. Test 
results were assumed to be conditionally dependent, with 
Bayesian prior distributions on sensitivity, specificity, and 
prevalence set using   BetaBuster 1.0 (https ://betab uster 
.softw are.infor mer.com/). The analysis was implemented 
in R Studio version 1.1.456 using the ‘lcaR’ model written 




A total of 720 individuals were sampled, with a median 
age of 27  years (IQR = 25  years), of whom 280 (38.9%) 
were male (Table  1). The most common occupations 
were student (34.4%) and housewife (41.9%) (Table 1). A 
total of 505 (70.1%) contacts lived within the household 
of an index case, and 215 (29.9%) lived within a neigh-
bouring household (Table 1).
A total of 69 individuals were positive for at least 
one diagnostic test, with a median age of 30 (IQR = 25) 
(Table 1). Of those, 31 (44.9%) were male (Table 1). The 
most common occupations within the 69 individu-
als were student (33.3%) and housewife (37.7%), and 
50 (72.5%) lived within the household of an index case 
(Table 1). The 69 asymptomatic cases were spread across 
59 (21.4%) of the 276 index cases. Of those 59 index 
cases, the median percentage positivity of the contacts 
was 33.3% (IQR = 25).
The 720 contacts were associated with VL cases 
(66.1%)—made up of new VL cases (90.1%), relapsed 
VL (9.5%), and VL treatment failure (0.4%)—or PKDL 
cases (33.9%) (Table  1). Of the 242 PKDL index cases 
with known rash type, 230 (95.0%) presented with macu-
lar rash, four (1.7%) with macular and papular rash, six 
(2.5%) with nodular and macular rash, and two (0.8%) 
with macular, nodular, and papular rash (Table  1). The 
69 asymptomatic cases were associated with new VL 
cases (49.3%) or PKDL cases (50.7%), with the majority 
of such PKDL cases presenting with macular rash (94.3%) 
(Table 1).
Estimates of asymptomatic infection in contacts of index 
cases using tests to detect active infection
Of the 720 participants screened, 69 (9.6%) were posi-
tive by at least one test. Of the 720 asymptomatic DNA 
samples screened, seven (1.0%) were positive by kDNA 
qPCR, with a mean Ct value of 31.9 (range 26.7–33.9). 
Urine samples were screened with the Leishmania anti-
gen ELISA, of which 24 (3.3%) were found to be posi-
tive. Samples screened by DAT were considered positive 
at a titre of ≥ 1:1600. A total of 28 (3.9%) samples were 
found to be DAT-positive, 11 (39.3%) of which had a titre 
≥ 1:12,800. LAMP detected six (0.8%), eight (1.1%), and 
three (0.4%) asymptomatic infections when DNA was 
extracted using Qiagen kits, boil and spin, and from DBS, 
respectively. For the purposes of further analysis, a par-
ticipant with a positive LAMP result from any one of the 
three extraction techniques was considered LAMP-posi-
tive, of which there were 15 (2.1%).
Leishmania antigen ELISA and the DAT identified the 
highest proportion of positive subjects. Only one (0.1%) 
subject was identified as positive by all four diagnostic 
methods, two (0.3%) were identified by two diagnostic 
Table 1 Index cases were classified as new VL cases, relapsed VL 
cases, VL treatment failure, or PKDL
Of the 720 contacts, 476 (66.1%) were associated with VL cases, and 244 (33.9%) 
were associated with PKDL cases. Of the 69 participants positive for at least one 





Median age (IQR) 27 (25) 30 (25)
Male 280 (38.9) 31 (44.9)
Occupation
 Students 248 (34.4) 23 (33.3)
 Housewives 301.68 (41.9) 26 (37.7)
Lives within the household of an 
index case
505 (70.1) 50 (72.5)
VL 476 (66.1) 34 (49.3)
 New VL case 429/476 (90.1) 34/34 (100.0)
 Relapsed VL case 45/476 (9.5) 0
 VL treatment failure 2/476 (0.4) 0
Post–kala azar dermal leishmaniasis 
(PKDL)
244 (33.9) 35 (50.7)
 Macular rash 230/244 (95.0) 33/35 (94.3)
 Macular and papular rash 4/244 (1.7) 0
 Nodular and macular rash 6/244 (2.5) 0
 Macular, nodular, and papular rash 2/244 (0.8) 1/35 (2.9)
 Rash type unknown 2/244 (0.8) 1/35 (2.9)
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methods, and 66 (9.2%) were identified by one diagnos-
tic method only. In the 69 asymptomatic participants, 26 
(37.7%) were positive by DAT only, and six (8.7%) were 
positive by qPCR only. Of the 24 (34.8%) participants 
positive by ELISA, three (4.3%) were positive by at least 
one other test (Fig.  1). Generally, poor agreement was 
found between tests. However, antigen and molecular 
tests showed better agreement in combination compared 
to the same tests in combination with serology (Table 2). 
In combination, the DAT and Leishmania antigen ELISA 
capture all participants positive by more than one of the 
four tests.
Risk factors for asymptomatic VL
Logistic regression was used to confirm risk factors associ-
ated with being positive for at least one of the four diag-
nostic tests. Age, gender, occupation, and living within 
the index household compared to neighbouring house-
holds were not found to be associated with asymptomatic 
infection. The index case being a PKDL case (OR 1.94, 
p = 0.009), specifically macular PKDL (OR 2.12, p = 0.004), 
was found to be significantly associated with being positive 
by at least one of the four tests.
Latent class analysis to estimate infection status 
and diagnostic accuracy in the absence of a gold standard
In the absence of a single reference standard or a com-
posite reference standard, latent class analysis (LCA) was 
used to estimate infection status. LCA estimated qPCR, 
LAMP, DAT, and Leishmania antigen ELISA to have sen-
sitivity (2.5–97.5 percentiles) of 85.6% (55.1–99.5), 99.8% 
(99.2–99.9), 97.5% (90.5–99.9), and 98.9% (96.2–99.9) 
and specificity of 96.1% (94.7–97.5), 96.7% (95.3–97.8), 
99.0% (98.1–99.6), and 97.9% (96.7–98.9), respectively. 
The prevalence of L. donovani asymptomatic infection in 
VL and PKDL contacts in Bangladesh was estimated to 
be 0.3% (0.03–0.7).
Discussion
In this study, we assessed the utility of the DAT, qPCR, 
LAMP, and Leishmania antigen ELISA for detection of 
asymptomatic Leishmania infection in household or 
neighbouring contacts of VL and PKDL index cases in 
endemic regions of Bangladesh. Both the DAT and Leish-
mania antigen ELISA capture all samples which are posi-
tive by more than one test, and both utilise sample types 
that have a relatively non-invasive sample collection, 
which can be transported back to a central laboratory for 
testing.
The DAT detected the highest proportion of positive 
individuals. The DAT detects anti-Leishmania antibod-
ies that could be circulating from a previously cleared 
asymptomatic infection. It is not possible to ascertain the 
time of infection in this cohort as it may be in a symp-
tomatic cohort. However, a recent study found that DAT 
titres could be a useful tool to monitor transmission in 
an elimination setting during repeat surveys [14]. Plate-
to-plate variation with the DAT in manufacturing and 
reading, and the relatively low-throughput nature have 
been previously suggested to be a limitation of this assay 
for monitoring and surveillance purposes [24]. Our find-
ings are in concordance with previous studies in Bangla-
desh and India which used serological methods to detect 
asymptomatic infection [25, 26]. Whereas qPCR requires 
more laboratory infrastructure, the Leishmania antigen 
Fig. 1 Asymptomatic infection was detected in 69 (9.6%) contacts 
by a combination of four diagnostic tests. DAT was positive in 28 
(40.6%) participants, 26 (37.7%) of whom were positive for DAT alone, 
and 11/28 (39.3%) of whom had a titre greater than 1:12,800. qPCR 
was positive in seven (10.1%) participants, six (8.7%) of whom were 
positive for qPCR alone. LAMP was positive in 15 (21.7%) participants, 
13 (18.8%) of whom were positive for LAMP alone. Leishmania 
antigen ELISA was positive in 24 (34.8%) participants, of whom 21 
(30.4%) were positive for ELISA alone and three (4.3%) were positive 
by ELISA and at least one other test
Table 2 Kappa scores and agreement for four diagnostic tests in 
69 asymptomatic participants
Test combination Agreement (%) Kappa score p value
DAT and Leishmania ELISA 30.4 − 0.476 6.8 × 10−5
DAT and qPCR 52.2 − 0.126 0.135
DAT and LAMP 40.6 − 0.330 0.003
Leishmania ELISA and qPCR 58.0 − 0.110 0.230
Leishmania ELISA and LAMP 49.3 − 0.225 0.049
LAMP and qPCR 71.0 − 0.055 0.614
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ELISA and LAMP are relatively simple techniques suit-
able for use in resource-poor settings. Furthermore, the 
Leishmania antigen ELISA requires a non-invasive urine 
sample and is relatively high-throughput, which may aid 
in screening of high numbers of asymptomatic contacts.
PKDL cases are a potential reservoir of Leishmania 
infection, with experimental infectivity to sand flies esti-
mated to be between 32 and 53% [27]. Here, we dem-
onstrate that a risk factor for asymptomatic infection is 
living close to a PKDL case, specifically macular PKDL. 
This follows the launch of the World Health Organiza-
tion’s road map for neglected tropical diseases 2021–
2030, which identifies early detection through methods 
such as active case detection and development of treat-
ments and diagnostics for both VL and PKDL, as criti-
cal actions for the elimination of VL as a public health 
concern [28]. Our data and the road map highlight the 
importance of diagnosis and follow-up of PKDL cases, in 
recognition of their potential role in transmission.
Previous studies have identified risk factors for VL 
broadly linked to poverty, such as mud walls, with sleep-
ing off the floor found to reduce the risk [29]. Proxim-
ity to a previous VL case was identified as a risk factor 
for VL in Bangladesh [30]. No difference based on sex, 
occupation, or income, among others, was seen in an 
analysis of risk factors in the same study [30]. Age trends 
associated with VL infection were found to vary between 
studies; however, the prevalence of seropositivity was 
generally found to increase with age [31].
The specificity of all diagnostics falls below 100% 
for identification of L. donovani asymptomatic infec-
tion, according to the LCA conducted, and thus we may 
expect some false positives on a cohort of this size. This is 
more probable for the antibody detection test DAT than 
for the direct detection tests LAMP and antigen ELISA. 
Therefore, we have looked for overlap in tests which were 
positive. We acknowledge that sample size may have 
limited our analysis of risk factors. Additionally, we use 
latent class analysis to estimate the probability that a par-
ticipant tests positive at a population level; however, we 
do not apply this at the individual level for further analy-
sis, given the potential for LCA to be unstable. A further 
limitation of the study is the lack of follow-up data, and 
therefore the accuracy of the tests as predictors of pro-
gression to clinical disease is unknown.
Conclusions
In an elimination setting such as Bangladesh, where dis-
ease reservoirs are anthroponotic, a relatively simple test 
such as the Leishmania antigen ELISA, which requires 
a non-invasive urine sample and detects active infec-
tion, may be of benefit in combination with serology for 
surveillance and monitoring of Leishmania transmission. 
Since living with or close to a macular PKDL patient is 
a risk factor for asymptomatic infection, we propose the 
follow-up of contacts with PKDL patients as an opera-
tional priority. Development of an antigen detection test 
in RDT format would be of benefit to identify those con-
tacts in the field.
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